User:Chickpecking/sandbox

= Believe Big = Believe Big is a Christian nonprofit registered 501c3 established by Ivelisse page in 2011 for the purpose of "bridging the gap between conventional and complementary medicine for fighting cancer."

Ivelisse Page
At the age of 37 Ivelisse was diagnosed with colon cancer. She used mistletoe therapy in combination with surgery to treat her Stage IV colon cancer and remains cancer free. Ivelisse has appeared as the subject of newscasts. She attributes her complete remission from Stage IV colon cancer partially to the use of mistletoe in her treatment. Dr Diaz, Page's treating oncologist at Johns Hopkins noted “That’s a universal feature I’ve seen in all patients who get mistletoe. Their colour improves; they have more energy.” Ivelisse gave the keynote address at the 2017 Association of Fundraising Professionals Maryland chapter conference.

Activities
Believe Big has organized several fundraisers.

They have enlisted two local private schools' Lacrosse teams in a fundraiser.

Believe Big has organized a mug activity where cancer patients are gifted a mug hand decorated and inscribed with inspirational phrases.

Mistletoe Patients in the News
Jeff Charles, the longtime announcer for the ECU Pirates is an outspoken supporter of mistletoe. He contracted colon cancer in 2012 and added intravenous mistletoe to his chemotherapy regimen. "Because this therapy worked so well, and is working so well, I feel a responsibility and just an obligation to get the word out to as many people as I can about mistletoe therapy and a natural approach to killing cancer," Charles said.

In 2014 several patients and their oncologists were featured on live television focusing on their choice to use mistletoe in treating their cancers.

Ivelisse's success with cancer has been noted in cancer journals and news reports. In 2013 the Baltimore Sun interviewed Page ad ran a story on the Johns Hopkins clinical trial with mistletoe. In 2017 Up2Me Magazine show interviewed Ivelisse on its radio program.

Conclusions from Systemic Reviews
A 2014 Cochrane review concluded there is insufficient evidence to support the use or safety of low dose naltrexone in active Crohn's disease due to the extremely limited data though the data suggested benefit and lack of harm.

A 2015 review from the Norwegian Institute of Public Health noted that there was currently insufficient evidence to determine whether low-dose naltrexone is effective and safe in treating Crohn's disease, multiple sclerosis, fibromyalgia, cancer, HIV, addiction problems and various chronic pain disorders and opioid dependence.